Effect of mepindolol on serum lipids

A. Martignoni, G. Perani, G. Finardi, E. Mastropasqua, R. Fogari

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In view of the postulated association between plasma lipids and the development of atherosclerosis, there is growing interest in the effects of beta blockers on plasma lipids. This study was undertaken to investigate whether a nonselective beta blocker, such as mepindolol, which possesses intrinsic sympathomimetic activity, causes significant changes in serum lipids, particularly in their distribution among the different lipoproteins. Eighteen healthy subjects, twelve males and six females, were given mepindolol orally, daily doses of 0.2 mg/kg averaging 10-15 mg. Pre- and post-treatment fasting total serum cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides were evaluated; the ratio LDL cholesterol/HDL cholesterol was also calculated. Total cholesterol did not change significantly after treatment with mepindolol (-1.9 mg%), whereas a small and nonsignificant decrease was observed in LDL cholesterol (-6 mg%); no change was found in HDL cholesterol (-0.2 mg%). Serum triglycerides showed a significant increase (+20.9 mg%, p

Original languageEnglish
Pages (from-to)543-545
Number of pages3
JournalInternational Journal of Clinical Pharmacology Therapy and Toxicology
Volume20
Issue number11
Publication statusPublished - 1982

Fingerprint

LDL Cholesterol
HDL Cholesterol
Lipids
Serum
Cholesterol
Plasmas
Sympathomimetics
Lipoproteins
Fasting
Atherosclerosis
Healthy Volunteers
Triglycerides
Therapeutics
mepindolol
low density lipoprotein triglyceride

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology (medical)

Cite this

Effect of mepindolol on serum lipids. / Martignoni, A.; Perani, G.; Finardi, G.; Mastropasqua, E.; Fogari, R.

In: International Journal of Clinical Pharmacology Therapy and Toxicology, Vol. 20, No. 11, 1982, p. 543-545.

Research output: Contribution to journalArticle

Martignoni, A. ; Perani, G. ; Finardi, G. ; Mastropasqua, E. ; Fogari, R. / Effect of mepindolol on serum lipids. In: International Journal of Clinical Pharmacology Therapy and Toxicology. 1982 ; Vol. 20, No. 11. pp. 543-545.
@article{02bfbf0db16b45b4bcfcec8b121681e2,
title = "Effect of mepindolol on serum lipids",
abstract = "In view of the postulated association between plasma lipids and the development of atherosclerosis, there is growing interest in the effects of beta blockers on plasma lipids. This study was undertaken to investigate whether a nonselective beta blocker, such as mepindolol, which possesses intrinsic sympathomimetic activity, causes significant changes in serum lipids, particularly in their distribution among the different lipoproteins. Eighteen healthy subjects, twelve males and six females, were given mepindolol orally, daily doses of 0.2 mg/kg averaging 10-15 mg. Pre- and post-treatment fasting total serum cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides were evaluated; the ratio LDL cholesterol/HDL cholesterol was also calculated. Total cholesterol did not change significantly after treatment with mepindolol (-1.9 mg{\%}), whereas a small and nonsignificant decrease was observed in LDL cholesterol (-6 mg{\%}); no change was found in HDL cholesterol (-0.2 mg{\%}). Serum triglycerides showed a significant increase (+20.9 mg{\%}, p",
author = "A. Martignoni and G. Perani and G. Finardi and E. Mastropasqua and R. Fogari",
year = "1982",
language = "English",
volume = "20",
pages = "543--545",
journal = "International Journal of Clinical Pharmacology and Therapeutics",
issn = "0174-4879",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "11",

}

TY - JOUR

T1 - Effect of mepindolol on serum lipids

AU - Martignoni, A.

AU - Perani, G.

AU - Finardi, G.

AU - Mastropasqua, E.

AU - Fogari, R.

PY - 1982

Y1 - 1982

N2 - In view of the postulated association between plasma lipids and the development of atherosclerosis, there is growing interest in the effects of beta blockers on plasma lipids. This study was undertaken to investigate whether a nonselective beta blocker, such as mepindolol, which possesses intrinsic sympathomimetic activity, causes significant changes in serum lipids, particularly in their distribution among the different lipoproteins. Eighteen healthy subjects, twelve males and six females, were given mepindolol orally, daily doses of 0.2 mg/kg averaging 10-15 mg. Pre- and post-treatment fasting total serum cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides were evaluated; the ratio LDL cholesterol/HDL cholesterol was also calculated. Total cholesterol did not change significantly after treatment with mepindolol (-1.9 mg%), whereas a small and nonsignificant decrease was observed in LDL cholesterol (-6 mg%); no change was found in HDL cholesterol (-0.2 mg%). Serum triglycerides showed a significant increase (+20.9 mg%, p

AB - In view of the postulated association between plasma lipids and the development of atherosclerosis, there is growing interest in the effects of beta blockers on plasma lipids. This study was undertaken to investigate whether a nonselective beta blocker, such as mepindolol, which possesses intrinsic sympathomimetic activity, causes significant changes in serum lipids, particularly in their distribution among the different lipoproteins. Eighteen healthy subjects, twelve males and six females, were given mepindolol orally, daily doses of 0.2 mg/kg averaging 10-15 mg. Pre- and post-treatment fasting total serum cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides were evaluated; the ratio LDL cholesterol/HDL cholesterol was also calculated. Total cholesterol did not change significantly after treatment with mepindolol (-1.9 mg%), whereas a small and nonsignificant decrease was observed in LDL cholesterol (-6 mg%); no change was found in HDL cholesterol (-0.2 mg%). Serum triglycerides showed a significant increase (+20.9 mg%, p

UR - http://www.scopus.com/inward/record.url?scp=0019905924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019905924&partnerID=8YFLogxK

M3 - Article

C2 - 7174157

AN - SCOPUS:0019905924

VL - 20

SP - 543

EP - 545

JO - International Journal of Clinical Pharmacology and Therapeutics

JF - International Journal of Clinical Pharmacology and Therapeutics

SN - 0174-4879

IS - 11

ER -